Stroke Trials Registry

Tizanidine
Zanaflex® DS 103-282

Action
Antispasticity agent - centrally-acting selective alpha 2 adrenoreceptor agonist.

Status
Tizanidine is approved by the US FDA for management of increased muscle tone associated with spasticity. This is based on studies of spinal cord injury and multiple sclerosis. Dose titration safety and efficacy study in stroke patients reported 2/00.

Trial(s)
= Ongoing
= Completed

Web Links and Publications

Elan Pharmaceuticals Web Site.

Prospective assessment of tizanidine for spasticity due to acquired brain injury.
Arch Phys Med Rehabil 2001 Sep;82(9):1155-63

An Open-Label Dose Titration Safety and Efficacy Study of Zanaflex® (Tizanidine HCl) in the Treatment of Chronic Spasticity Associated with Stroke.
Stroke 2000 31(1): 295

Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam.
Adv Ther. 1998 Jul-Aug;15(4):241-51.

A double-blind, long-term study of tizanidine ('Sirdalud') in spasticity due to cerebrovascular lesions.
Curr Med Res Opin. 1989;11(6):398-407.

UID: 57